journal article·2024-12-10

Luteolin Functionalized Zinc Oxide Nanoparticles for Cancer Therapy Based on Autophagy Activation and EMT Inhibition

Yan Gao, Jinwen Zhu, Xingye Zheng, Guanghui Lin, Peng Miao

Langmuir· Volume 40· Issue 49
Publisher page

Abstract

Natural bioactive compounds have become increasingly important antitumor and antimicrobial agents due to their high therapeutic potential and low systemic toxicity. However, they also have significant drawbacks like nontumor targeting and low bioavailability, which limit their wide therapeutic applications. There is an urgent need for a safe and compatible nanoparticle-mediated drug delivery system for the efficient transport of drug candidates into tumor tissues. In this paper, amine-modified zinc oxide nanoparticles are synthesized to load luteolin. The functionalized nanoparticles exhibit good synergistic effects in terms of antitumor and antibacterial activities. They show significant induction of oxidative stress and antitumor effects, while no significant inhibitory effect on normal cells is observed, suggesting that the nanocomposites have good targeting of cancer cells. Autophagy activation and EMT inhibition effects are studied to explain the good antitumor performances. The prepared nanocomposites are demonstrated to be attractive candidates for cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Autophagy in Disease and Therapy · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China

School of Biomedical Engineering, Sun Yat-Sen University, Shenzhen 518707, China

University of Science and Technology of China, Hefei 230026, China

Funding

Outstanding Youth Foundation of Jiangsu Province

References (31)

Show source-provided references
1. 10.1038/s41573-020-00114-z10.1038/s41573-020-00114-z ↗
2. 10.1038/s41589-019-0304-810.1038/s41589-019-0304-8 ↗
3. 10.1038/s41467-019-11622-x10.1038/s41467-019-11622-x ↗
4. 10.1021/acschemneuro.1c0015710.1021/acschemneuro.1c00157 ↗
5. 10.1021/acsbiomaterials.8b0022010.1021/acsbiomaterials.8b00220 ↗
6. 10.1021/acs.jpcb.7b0576610.1021/acs.jpcb.7b05766 ↗
7. 10.1021/acs.jafc.8b0327310.1021/acs.jafc.8b03273 ↗
8. 10.1021/acsanm.4c0054610.1021/acsanm.4c00546 ↗
9. 10.1016/j.numecd.2020.02.01410.1016/j.numecd.2020.02.014 ↗
10. 10.2147/IDR.S25336310.2147/IDR.S253363 ↗
11. 10.1186/s12935-020-01634-910.1186/s12935-020-01634-9 ↗
12. 10.1021/ja806429q10.1021/ja806429q ↗
13. 10.1021/acs.accounts.1c0059210.1021/acs.accounts.1c00592 ↗
14. 10.1021/acs.molpharmaceut.2c0055310.1021/acs.molpharmaceut.2c00553 ↗
15. 10.1016/j.drudis.2017.08.00610.1016/j.drudis.2017.08.006 ↗
16. 10.1021/acssuschemeng.7b0143310.1021/acssuschemeng.7b01433 ↗
17. 10.1007/s13273-014-0043-610.1007/s13273-014-0043-6 ↗
18. 10.1021/acsami.6b1377610.1021/acsami.6b13776 ↗
19. 10.1021/acsnano.8b0684610.1021/acsnano.8b06846 ↗
20. 10.1021/acsbiomaterials.0c0088310.1021/acsbiomaterials.0c00883 ↗
21. 10.1016/j.cbi.2016.07.02810.1016/j.cbi.2016.07.028 ↗
22. 10.1088/0957-4484/17/4/02210.1088/0957-4484/17/4/022 ↗
23. 10.1021/jp509752s10.1021/jp509752s ↗
24. 10.1038/s41419-019-1447-y10.1038/s41419-019-1447-y ↗
25. 10.1021/acs.langmuir.5b0226610.1021/acs.langmuir.5b02266 ↗
26. 10.1016/j.bbrc.2017.10.04210.1016/j.bbrc.2017.10.042 ↗
27. 10.1016/j.cell.2022.02.02710.1016/j.cell.2022.02.027 ↗
28. 10.1016/j.metabol.2023.15574710.1016/j.metabol.2023.155747 ↗
29. 10.1038/s41573-024-00979-410.1038/s41573-024-00979-4 ↗
30. 10.1007/s00280-017-3299-410.1007/s00280-017-3299-4 ↗
31. 10.1002/iid3.44310.1002/iid3.443 ↗